The market for telmisartan, a medication used to treat high blood pressure and heart failure, is likely to be significant. Telmisartan is part of a class of drugs known as angiotensin receptor blockers (ARBs) and is one of the most commonly prescribed medications for hypertension. According to a report by Allied Market Research, the global telmisartan market was valued at $3,453 million in 2019 and is projected to reach $4,258 million by 2027, at a CAGR of 3.4%. Factors driving the market growth include the increasing prevalence of hypertension and heart failure, as well as the growing use of telmisartan in combination therapies.
Get a PDF Sample of the Telmisartan Industry : https://www.alliedmarketresearch.com/request-sample/10658
The key players profiled in this report include
Abbott Laboratories, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Cipla Inc., Glaxosmithkline Plc (GSK), Mylan N.V., Sanofi, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila
The COVID-19 pandemic has had a significant impact on the telmisartan market, as well as the broader pharmaceutical industry. The pandemic has caused disruptions in the supply chain and distribution of drugs, leading to shortages and delays in the availability of medications. Additionally, the focus on COVID-19 research and development has shifted resources and funding away from other areas of pharmaceutical research and development.
On the other hand, the pandemic has also led to an increase in demand for medications to treat hypertension and heart failure, as people with these conditions are at higher risk for severe illness from COVID-19. This increased demand for telmisartan and other hypertension medications may drive growth in the market.
Some key findings of studies on the telmisartan market include:
- The global telmisartan market is projected to grow at a CAGR of 3.4% from 2020 to 2027.
- The increasing prevalence of hypertension and heart failure is a major driver of market growth.
- The use of telmisartan in combination therapies is also expected to drive market growth.
- The Asia-Pacific region is expected to be the fastest-growing market for telmisartan due to the increasing population and the rising incidence of hypertension.
- The generics segment is expected to grow at the highest CAGR during the forecast period due to the increasing adoption of generic drugs and their lower cost compared to branded drugs.
- The COVID-19 pandemic has had a mixed impact on the telmisartan market, with disruptions to supply and distribution offset by increased demand for the medication.
By y indication, hypertension and cardiovascular risk reduction are likely to be two of the main segments.
Hypertension: Telmisartan is primarily used to treat hypertension, also known as high blood pressure. The growing prevalence of hypertension, particularly in developing countries, is expected to drive growth in the telmisartan market for the hypertension indication. As hypertension is a major risk factor for heart disease, stroke, and kidney disease, the increasing awareness about hypertension and its complications will also fuel the growth of the telmisartan market for hypertension indication.
Cardiovascular Risk Reduction: Telmisartan is also used for the treatment of cardiovascular risk reduction. As telmisartan has been shown to reduce the risk of cardiovascular events in high-risk patients, it is increasingly being used in combination with other medications to reduce the risk of cardiovascular disease. This is expected to drive growth in the telmisartan market for the cardiovascular risk reduction indication.
Overall, the hypertension indication is likely to be the largest segment of the telmisartan market, as hypertension is a common condition that affects a large proportion of the population. However, the cardiovascular risk reduction indication is also expected to see significant growth, as telmisartan is increasingly being used in combination with other medications to reduce the risk of cardiovascular disease.
by distribution channel, hospital pharmacies, drug stores and retail pharmacies, and online pharmacies are likely to be the main segments.
Hospital Pharmacies: Hospital pharmacies are likely to be a significant distribution channel for telmisartan, as the medication is often prescribed for patients with hypertension and heart failure who are being treated in a hospital setting. Hospital pharmacies have the advantage of being able to provide the medication directly to patients, and also have the capability to manage a stock of medication and handle insurance payments.
Drug Stores and Retail Pharmacies: Drug stores and retail pharmacies are also likely to be a significant distribution channel for telmisartan. These pharmacies are easily accessible to patients and provide a convenient way for patients to pick up their prescriptions. Many retail pharmacies also have online ordering and home delivery options.
Online Pharmacies: The online pharmacies are becoming increasingly popular for the distribution of telmisartan and other medications. Online pharmacies offer the convenience of ordering medication from home and can be a cost-effective option for patients. These pharmacies also offer home delivery services and have the capability to handle insurance payments.
Overall, the distribution of telmisartan is likely to be a combination of all these three channels, with hospital pharmacies being the primary distribution channel, followed by drug stores and retail pharmacies, and online pharmacies. The distribution channel may vary depending on the region and the population density.
Download the Complete Research Study Here in PDF Format @https://www.alliedmarketresearch.com/checkout-final/e3d922252bc370089bdc1a7632a801c1
A Table of Contents (TOC)
- Executive Summary
- Market Overview
- Market Dynamics
- Global Telmisartan Market, By Indication
- Global Telmisartan Market, By Distribution Channel
- Global Telmisartan Market, By Region
- Competitive Landscape
- Company Profiles
- Conclusion
- Appendix